KBC Group NV purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 3,020 shares of the company’s ...
Hosted on MSN29d
Scholar Rock's chief medical officer sells shares worth $249,935The RSUs, granted on February 12, 2024, vest annually over four years, contingent upon continued service with Scholar Rock.Following this transaction, Marantz holds 67,200 shares, consisting of ...
Shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) have received an average recommendation of “Buy” from the ... Several large investors have recently modified their holdings ...
Truist Financial analyst Jailendra Singh reiterated a Buy rating on Scholar Rock Holding (SRRK – Research Report) today. The company’s shares closed last Friday at $40.49. Discover ...
Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance. At Scholar Rock Holding Corp, recent insider activity has drawn attention.
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global ...
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...
CAMBRIDGE, Mass., February 14, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback